TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,707.97+0.63%Nasdaq 10029,639.08+1.55%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$216.99+1.34%NYSE:TSM$421.46+2.14%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,142.91−0.54%Brent$109.44−0.34%BTC$81,741.07−0.33%ETH$2,390.55−0.70%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,707.97+0.63%Nasdaq 10029,639.08+1.55%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$216.99+1.34%NYSE:TSM$421.46+2.14%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,142.91−0.54%Brent$109.44−0.34%BTC$81,741.07−0.33%ETH$2,390.55−0.70%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Open 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Revolution Medicines Inc · News · TradingHolo

Markets › United States › NAS › RVMD

R

Revolution Medicines Inc

NAS:RVMDHealthcareNASDAQ:NBINASDAQ:NQUSLG

$182.17+2.37%LiveIn session · ≈ AED 669.02 · Market cap $39.05B · Next earnings Wed 4 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

RVMD news

Headlines tagged to this company

DORevolution Medicines Price Target Raised to $241.00/Share From $240.00 by Truist Securities

Dow Jones Newswires · 6 h ago

TRTruist Securities maintains Buy rating on Revolution Medicines, $241 price target

TradingView · 6 h ago

SELilly, Pfizer, J&J among winners of EU drug recommendations this month

Seeking Alpha · 3 d ago

DORevolution Medicines Price Target Maintained With a $275.00/Share by Needham

Dow Jones Newswires · 4 d ago

RERevolution Medicines' Europe efforts signal solo launch ambitions for cancer drug

Reuters · 4 d ago

DORevolution Medicines Pancreatic Cancer Treatment Gets Positive Opinion From EU Regulators

Dow Jones Newswires · 4 d ago

SERevolution Medicines' Rasonque gains positive CHMP opinion

Seeking Alpha · 4 d ago

REEMA panel backs approval of Revolution's pancreatic cancer drug

Reuters · 4 d ago

REEMA recommends approval of Revolution's pancreatic cancer drug

Reuters · 4 d ago

GLRevolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

GlobeNewswire · 4 d ago

TRNeedham reiterates Buy rating on Revolution Medicines, $275 price target

TradingView · 4 d ago

DORevolution Medicines Is Maintained at Outperform by RBC Capital

Dow Jones Newswires · 5 d ago

TRRBC Capital maintains Outperform rating on Revolution Medicines, $260 price target

TradingView · 5 d ago

DORevolution Medicines Price Target Raised to $259.00/Share From $251.00 by RBC Capital

Dow Jones Newswires · 11 d ago

DORevolution Medicines Is Maintained at Buy by Truist Securities

Dow Jones Newswires · 12 d ago

GLRevolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

GlobeNewswire · 14 d ago

DORevolution Medicines Price Target Announced at $318.00/Share by Brookline Capital

Dow Jones Newswires · 21 d ago

FINuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset

financewire · 24 d ago

SENvidia-backed AI drugmaker Iambic Therapeutics seeks U.S. listing

seekingalpha · 28 d ago

SE10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades

seekingalpha · 32 d ago